Vemurafenib medical insurance reimbursement scope

Vemurafenib is a prescription drug, and the scope of medical insurance reimbursement is limited to the treatment of unresectable or metastatic melanoma that is determined by a CFDA-approved detection method BRAF V600 mutation-positive.

Vemurafenib is the first molecularly targeted therapy approved in the United States and Europe for the treatment of advanced melanoma. Its mechanism of action includes selective inhibition of mutated BRAF V600Ekinase, resulting in reduced signaling in the abnormal mitogen-activated protein kinase (MAPK) pathway.

The recommended dose of vemurafenib is 960 mg twice daily and 240 mg twice daily. Based onhow the patientresponds to treatment, the doctor may adjust the patient's dose. Patients typically continue taking vemurafenib until their melanoma worsens or they experience unacceptable side effects.

Vemurafenib is committed to targeting melanoma cells, with the goals: slowing the growth or spread of melanoma and helping patients live longer. Results from a largePhase III clinical trial showed thatvemurafenibimproved patient outcomes better than the chemotherapy drugDTIC (dacarbazine). Vemurafenib blocks the activity of a mutant protein called BRAF, a molecule that helps regulate cell growth. BRAFmutations signal cells to develop abnormally and divide out of control, and these cells grow into melanoma. Vemurafenib is an original drug available in Türkiye. The retail price in pharmacies is 240mg, 56 tablets2more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.